PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

• Published in: Molecular cancer Vol. 19; no. 1; pp. 49 - 15
• Main Authors: Zhu, Heng, Wei, Miaoyan, Xu, Jin, Hua, Jie, Liang, Chen, Meng, Qingcai, Zhang, Yiyin, Liu, Jiang, Zhang, Bo, Yu, Xianjun, Shi, Si
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.03.2020; BioMed Central; BMC
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Biological markers; Biotechnology; BRCA; BRCA mutations; Breast cancer; Cancer therapies; Cancer treatment; Carcinogenesis; Cell death; Chemotherapy; Chemotherapy resistance; Clinical trials; Deoxyribonucleic acid; Development and progression; Diseases; DNA; DNA damage; DNA repair; Drugs; Gene mutation; Genes; Genetic aspects; Genetic research; Genomes; Health risk assessment; Homologous recombination repair; Humans; Kinases; Medical prognosis; Metastasis; Molecular modelling; Monosaccharides; Mutation; Olaparib; Ovarian cancer; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - pathology; PARP inhibitor; Polo; Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Prognosis; Proteins; Response rates; Review; Synthetic lethality; Talazoparib; Targeted cancer therapy; Therapeutic applications; Tumors; Homologous recombination repair; BRCA; Chemotherapy resistance; Pancreatic cancer; PARP inhibitor; Biomarkers; Synthetic lethality
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-020-01167-9

Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising research direction. Poly (ADP-ribose) polymerase (P...